Nosratabadi, MohsenAkhtari, JavadFaeli, LeilaHaghani, ImanAghili, Seyed RezaShokohi, TaherehHedayati, Mohammad TaghiZarrinfar, HosseinMohammadi, RasoulNajafzadeh, Mohammad JavadKhodavaisy, SadeghAl-Harrasi, AhmedJavan-Nikkhah, MohammadKachuei, RezaSalimi, MaryamFattahi, MahsaBadali, HamidAl Hatmi, Abdullah M. S.Abastabar, Mahdi2022-07-252022-07-252022-07-04Journal of Fungi 8 (7): 709 (2022)https://hdl.handle.net/20.500.12588/1066Fusarium species are filamentous fungi that cause a variety of infections in humans. Because they are commonly resistant to many antifungal drugs currently available in clinical settings, research into alternative targets in fungal cells and therapeutic approaches is required. The antifungal activity of miltefosine and four comparators, amphotericin B, voriconazole, itraconazole, and caspofungin, were tested in vitro against a collection of susceptible and resistant clinical (n = 68) and environmental (n = 42) Fusarium isolates. Amphotericin B (0.8 µg/mL) had the lowest geometric mean (GM) MICs/MECs values followed by miltefosine (1.44 µg/mL), voriconazole (2.15 µg/mL), caspofungin (7.23 µg/mL), and itraconazole (14.19 µg/mL). Miltefosine was the most effective agent against Fusarium isolates after amphotericin B indicating that miltefosine has the potential to be studied as a novel treatment for Fusarium infections.Attribution 4.0 United Stateshttps://creativecommons.org/licenses/by/4.0/miltefosineFusarium speciesantifungal drugsresistanceArticle2022-07-25